NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lumicell, Inc.

Lumicell, Inc.

Private
Newton, MassachusettsHealthcare & Life Scienceshttps://lumicell.com/

Last Round

Series D

Extension

Apr 22, 2025

Est. Valuation

$250M

Total Funding Raised

$202.05M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lumicell, Inc. is a medical device company that develops innovative fluorescence-guided surgical technologies to enable real-time detection and removal of residual cancerous tissue during surgery.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Application

Keywords

fluorescence-guided surgerycancer imaginglumpectomysurgical oncologyintraoperative imagingbreast cancer surgeryoptical imaging agentreal-time cancer detectionmedical deviceimage-guided surgerysurgical navigationtumor margin assessmentprecision surgerymedtechsurgical tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lumicell, Inc. Comparables

Compare Lumicell, Inc. with similar companies based on industry and business-model similarity.

Lumicell, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Lumicell, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionApr 22, 2025
Series DJul 11, 2024
Series CFeb 22, 2024
Series DJul 26, 2023
Series DMay 25, 2021
Debt
Apr 15, 2020

Lumicell, Inc. Investors

Notable investors and investment history

Lumicell, Inc. investors
InvestorRounds
National Cancer InstituteGrant
Furneaux CapitalSeries D
Kodiak Venture PartnersSeries C
BlueIOSeries D, Series C
Massachusetts Life Sciences CenterDebt
Rivas CapitalSeries D
Kinled HoldingSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Fluorescence-guided surgery platform is now a commercially approved Class III medical device.

  • Mar 1, 2026

    Expanding commercial launch of breast cancer surgery drug/device product.

Lumicell, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lumicell, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lumicell, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNewton, Massachusetts
Employee Range62
Year Founded2008
Last FundingApr 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.